2026-06-07
Written by Sofia Rodriguez
A new blood-filtering device has shown promise in treating patients with severe forms of ebola. Researchers believe it could help reduce mortality rates by removing the virus from the bloodstream.
New Technology Hopes to Save Lives in the Face of the Deadly Ebola Virus.
Physicians are facing a daunting challenge as they struggle to treat patients infected with the deadly Bundibugyo strain of Ebola. The virus has claimed thousands of lives over the past few years, and its spread is feared to be imminent. In response to this growing threat, researchers have turned their attention to experimental blood-filtering devices that can physically remove viral particles from the bloodstream.
These systems have been studied primarily as treatments for cancer, where they help remove tumor-derived particles, and in more common infectious diseases such as COVID-19 and hepatitis C. However, one such device was successfully deployed during the last major outbreak of Ebola, helping to drive down exceedingly high viral levels in one critically ill patient. The treatment has shown promise in slowing the progression of the disease, but its use remains a topic of debate among medical professionals.
The technology behind these devices is relatively simple. They are essentially tiny fibers coated with sticky proteins that latch onto sugar molecules that coat viruses like Ebola and trap them as blood passes through the system. In some cases, the Hemopurifier, one such device, has been used in conjunction with an intensive-care-grade dialysis machine to remove large amounts of viral particles from a patient's bloodstream.
In 2014, Aethlon Medical secured FDA authorization for its Hemopurifier system, which is capable of removing up to 253 million copies of the Ebola virus from a patient's blood. This treatment has shown remarkable promise in slowing the progression of the disease and even helping patients recover. However, its use remains largely experimental, and major logistical challenges remain.
One major obstacle is convincing physicians and health systems to adopt this new treatment paradigm. Many are skeptical about the effectiveness of physically removing viruses from a patient's bloodstream rather than targeting them with pharmaceuticals. Additionally, the equipment required for these devices can be costly and difficult to access in resource-constrained settings where Ebola outbreaks often occur.
Despite these challenges, researchers are working on developing lower-tech versions of blood-filtration systems that could potentially operate without hospital infrastructure or electricity. For example, a manual system described by patent filings from Stavro Medical would require a healthcare worker to push blood through a filter cartridge in batches or simply raise one reservoir above another to allow blood to flow downhill through the filter.
Aethlon Medical is also pursuing a more modest goal of developing a stripped-down version of its Hemopurifier system that could run through a standard IV line rather than requiring a thick catheter. While this technology is not yet ready for prime time, it represents an important step towards making blood filtration more accessible to patients in resource-constrained settings.
Ultimately, the use of these devices will depend on their ability to capture and remove viral particles from a patient's bloodstream effectively. If proven successful, they could represent a game-changing tool in the fight against Ebola and other infectious diseases. However, it is clear that much work remains to be done before these technologies can be widely adopted.
As the deadly Bundibugyo strain of Ebola continues to ravage parts of Central Africa, physicians are facing an unprecedented challenge. The virus has claimed thousands of lives over the past few years, and its spread is feared to be imminent. In response to this growing threat, researchers have turned their attention to experimental blood-filtering devices that can physically remove viral particles from a patient's bloodstream.
While these technologies hold promise, they also pose significant challenges for implementation. Convincing physicians and health systems to adopt a new treatment paradigm will require significant education and training. Additionally, access to the equipment required for these devices remains a major obstacle in many parts of the world where Ebola outbreaks often occur.
Despite these challenges, researchers remain hopeful that blood filtration can play a critical role in slowing the progression of the disease and even helping patients recover. As the situation continues to evolve, it is clear that much work remains to be done before these technologies can be widely adopted.
